 BOSTON and LONDON, Sept. 07, 2021 GLOBE NEWSWIRE -- Orchard Therapeutics Nasdaq: ORTX, a global gene therapy leader, today announced that the Compensation Committee of Orchards Board of Directors approved the grant of non-statutory stock options to four new employees to purchase an aggregate of 278,500 ordinary shares under Orchards 2020 Inducement Equity Plan. The awards were granted as an inducement material to the employees acceptance of employment with Orchard in accordance with Nasdaq Listing Rule 5635c4. 